论文部分内容阅读
[目的]探讨肝动脉化疗栓塞(TACE)联合重组人血管内皮抑制素介入治疗原发性肝细胞癌(HCC)的临床疗效。[方法]将52例HCC患者随机分为观察组和对照组各26例,观察组给予TACE联合重组人血管内皮抑制素介入治疗,对照组单纯给予TACE治疗,比较两组的不良反应、临床疗效及治疗前后AFP水平、肝外转移等情况。[结果]治疗后两组AFP水平、不良反应发生率等比较差异无统计学意义(P>0.05);观察组总有效率明显高于对照组(46.15%vs15.38%,χ2=6.753,P=0.034);术后1年的肝外转移发生率明显低于对照组(0vs23.08%,χ2=6.783,P=0.009)。[结论]TACE联合重组人血管内皮抑制素介入治疗HCC能提高疗效,有效地减少肿瘤肝外转移,安全有效。
[Objective] To investigate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with recombinant human endostatin in the treatment of primary hepatocellular carcinoma (HCC). [Methods] 52 HCC patients were randomly divided into observation group and control group, 26 cases in each group. TACE combined with recombinant human endostatin in the observation group and TACE group in the control group were compared. The adverse reactions and clinical effects And before and after treatment AFP levels, extrahepatic metastasis and so on. [Results] There was no significant difference in AFP level and incidence of adverse reactions between the two groups after treatment (P> 0.05). The total effective rate in the observation group was significantly higher than that in the control group (46.15% vs 15.38%, χ2 = 6.753, P = 0.034). The incidence of extrahepatic metastasis at 1 year after operation was significantly lower than that of the control group (0 vs. 23.08%, χ2 = 6.783, P = 0.009). [Conclusion] TACE combined with recombinant human endostatin in interventional treatment of HCC can improve the curative effect and effectively reduce the extrahepatic metastasis of tumor, which is safe and effective.